Truist Securities Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $68

Benzinga Newsdesk www.benzinga.com Positive 50.3%

Neg 0% Neu 0% Pos 50.3%

Truist Securities analyst Danielle Brill initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $68.